Novo Hims & Hers: Crackdown on Telehealth Knockoffs?
- Novo Nordisk terminated its collaboration with Hims & Hers Health on Monday, citing worries about the "illegal mass compounding and deceptive marketing" of Wegovy knockoffs.
- The announcement sent shares of Hims & Hers (HIMS) tumbling 28.98% to $45.61.
- The partnership, intended to broaden access to affordable obesity treatments via telehealth, lasted just over a month.
Novo Nordisk abruptly ended its partnership with hims & hers, a decisive move driven by concerns over the illegal mass compounding and deceptive marketing of Wegovy knockoffs, putting patient safety at risk. This crackdown on telehealth knockoffs caused Hims & hers health shares to tumble, marking meaningful market impact.The collaboration, aimed at broadening access to affordable obesity treatments, dissolved after just a month due to alleged violations. The Danish drugmaker targeted compounded semaglutide products, citing unapproved ingredients from Chinese suppliers with potential quality assurance issues. For more details, check out News Directory 3. Discover what’s next for this weight loss drug saga.
Novo Nordisk Ends Hims & Hers Partnership Over Wegovy Concerns
Updated June 24, 2025
Novo Nordisk terminated its collaboration with Hims & Hers Health on Monday, citing worries about the “illegal mass compounding and deceptive marketing” of Wegovy knockoffs. The pharmaceutical company stated these practices “put patient safety at risk.”
The announcement sent shares of Hims & Hers (HIMS) tumbling 28.98% to $45.61. Novo Nordisk (NVO) shares also fell, dropping 5.16% to $69.96.
The partnership, intended to broaden access to affordable obesity treatments via telehealth, lasted just over a month. Novo Nordisk accused hims & Hers of continuing to sell unauthorized compounded versions of its popular weight-loss drug, wegovy, despite the collaboration.
The companies initially announced their “long-term collaboration” in April, aiming to make obesity care “more accessible, more affordable, and more connected.” The deal offered FDA-approved Wegovy through the Hims & Hers platform for $599 monthly.
However, Novo Nordisk soured on the relationship, alleging that Hims & Hers Health failed to adhere to laws prohibiting mass sales of compounded drugs under the guise of personalization. Thay also claimed the company disseminated deceptive marketing that endangered patient safety.
the Danish drugmaker expressed particular concern about compounded semaglutide products using active ingredients from foreign suppliers in China,which the FDA had neither inspected nor approved. A Brookings Institution report cited by Novo Nordisk indicated that many of these Chinese suppliers had drug quality assurance violations.
Dave Moore, executive vice president of Novo Nordisk